Alternative

Inovio Receives Authorization from the US FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease — Recurrent Respiratory Papillomatosis (RRP) – BioSpace

  • RRP is a rare, potentially fatal orphan disease caused by Human Papillomavirus (HPV) 6 and 11
  • Inovio’s DNA medicine pipeline includes 15 clinical programs focused on HPV-associated diseases, cancer, and infectious diseases, including the novel coronavirus (2019-nCoV)

PLYMOUTH MEETING, Pa., Feb. 10,…

source website